Integrated Analysis of ECT2 and COL17A1 as Potential Biomarkers for Pancreatic Cancer

Figure 9

Prediction of potential drug responses. (a) Sensitivity of PD-1 treatment in high- and low-ECT2 groups. (b) Sensitivity of PD-1 treatment in high- and low-COL17A1 groups. (c) Differential chemotherapeutic responses in high- and low-ECT2 groups. (d) Differential chemotherapeutic responses in high- and low-COL17A1 groups.

(a)

(b)

(c)

(d)